Home/Suntec Medical/Chun‑Ting (Isaac) Cheng

C(

Chun‑Ting (Isaac) Cheng

Pre‑clinical Development

Therapeutic Areas

Oncology Central Nervous System Autoimmune Cardiovascular Infectious Diseases Gene Therapy Vaccines

Suntec Medical Pipeline

Drug	Indication	Phase
MINC‑trastuzumab	HER2‑positive breast cancer	Preclinical
MINC‑sunitinib	Renal cell carcinoma	Preclinical
MINC‑doxorubicin	Various solid tumors	Preclinical
MINC‑anti‑CD3	Autoimmune diseases	Preclinical

Leadership Team at Suntec Medical

Business Development

Bhuwnesh Agrawal

Corporate Executive Vice President, Strategy & BD

View full Suntec Medical profile